Blog

May 22, 2024, 04:25

Timothée Olivier: One of the most important and practice-changing piece this year

Timothée Olivier, Medical Oncologist at HUG – Geneva University Hospitals, shared a post on X by JAMA Oncology adding:

“One of the most important and practice-changing piece this year.
Everyone treating patients with melanoma should read this.
Conclusions are supported by clinical trials data and real-world outcome. Great work by Marco Donia and Vinay Prasad.

+link.”

Quoting JAMA Oncology’s post below.

“Viewpoint discusses use of anti–PD-1 monotherapy as the primary treatment option for patients with treatment-naive metastatic melanoma staining positive for PD-L1 over dual checkpoint inhibition therapy.”

View the article attached to the post.
Sources: Timothée Olivier/X and JAMA Oncology/X

anti–PD-1 monotherapy cancer clinical trials Geneva University Hospitals JAMA Oncology Marco Donia Melanoma OncoDaily Oncology Timothée Olivier Vinay Prasad

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage